Activating autoantibodies against G protein-coupled receptors in narcolepsy type 1

Show full item record



Permalink

http://hdl.handle.net/10138/329325

Citation

Orjatsalo , M , Partinen , E , Wallukat , G , Alakuijala , A & Partinen , M 2021 , ' Activating autoantibodies against G protein-coupled receptors in narcolepsy type 1 ' , Sleep Medicine , vol. 77 , pp. 82-87 . https://doi.org/10.1016/j.sleep.2020.11.038

Title: Activating autoantibodies against G protein-coupled receptors in narcolepsy type 1
Author: Orjatsalo, Maija; Partinen, Eemil; Wallukat, Gerd; Alakuijala, Anniina; Partinen, Markku
Other contributor: University of Helsinki, HUS Medical Imaging Center
University of Helsinki, Clinicum
University of Helsinki, HUS Neurocenter
University of Helsinki, Department of Neurosciences







Date: 2021-01
Language: eng
Number of pages: 6
Belongs to series: Sleep Medicine
ISSN: 1389-9457
DOI: https://doi.org/10.1016/j.sleep.2020.11.038
URI: http://hdl.handle.net/10138/329325
Abstract: Study objectives: Narcolepsy type 1 is a rare hypersomnia of central origin, which is caused by loss of hypothalamic neurons that produce the neuropeptides hypocretin-1 and -2. Hypocretin-containing nerve terminals are found in areas known to play a central role in autonomic control and in pain signaling. Cholinergic M2 receptors are found in brain areas involved with the occurrence of hallucinations and cataplexy. In addition to classical symptoms of narcolepsy, the patients suffer frequently from autonomic dysfunction, chronic pain, and hypnagogic/hypnopompic hallucinations. We aimed to test whether narcolepsy type 1 patients have autoantibodies against autonomic beta 2 adrenergic receptor, M2 muscarinic receptors, or nociception receptors. Methods: We tested the serum of ten narcolepsy type 1 patients (five female) for activating beta 2 adrenergic receptor autoantibodies, M2 muscarinic receptor autoantibodies, and nociception receptor autoantibodies. Results: Ten of ten patients were positive for muscarinic M2 receptor autoantibodies (P <0.001), 9/10 were positive for autoantibodies against nociception receptors (P <0.001), and 5/10 were positive for beta 2 adrenergic receptor autoantibodies (P <0.001). Conclusions: Narcolepsy type 1 patients harbored activating autoantibodies against M2 muscarinic receptors, nociception receptors, and beta 2 adrenergic receptors. M2 receptor autoantibodies may be related to the occurrence of cataplexy and, moreover, hallucinations in narcolepsy since they are found in the same brain areas that are involved with these symptoms. The occurrence of nociception receptor autoantibodies strengthens the association between narcolepsy type 1 and pain. The connection between narcolepsy type 1, autonomic complaints, and the presumed cardiovascular morbidity might be associated with the occurrence of beta 2 adrenergic receptor autoantibodies. On the other hand, the presence of the autoantibodies may be secondary to the destruction of the hypocretin pathways. (C) 2020 Elsevier B.V. All rights reserved.
Subject: AUTONOMIC CONTROL
CARDIOMYOPATHY
CATAPLEXY
HEART-RATE-VARIABILITY
Hypocretin
M2 muscarinic receptor autoantibodies
MUSCARINIC RECEPTORS
Narcolepsy type 1
Nociception receptor autoantibodies
Orexin
SCHIZOPHRENIA
SLEEP
STRIATUM
beta 2 adrenergic receptor autoantibodies
3124 Neurology and psychiatry
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1389945720305384_main.pdf 218.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record